SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 2
    Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. Medical progress. N Engl J Med. 2001; 345: 18901900.
  • 3
    Langendijk J, Slotman B, van der Waal I, et al. Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer. 2005; 104: 14081417.
  • 4
    AngKK, GardenAS, eds. Radiotherapy for Head and Neck Cancers, Indications and Techniques. 2nd ed. New York, NY: Lippincott Williams & Wilkins, 2002.
  • 5
    Nguyen L, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol. 2002; 3: 693701.
  • 6
    Cooper JS, Ang KK. Concomitant chemotherapy and radiation therapy certainly improves local control. Int J Radiat Oncol Biol Phys. 2005; 61: 79.
  • 7
    Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000; 47: 112.
  • 8
    Van den Bogaert W, Van der Leest A, Rijnders A, et al. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol. 1995; 36: 177182.
  • 9
    Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys. 1995; 31: 11411164.
  • 10
    Wijers O, Levendag P, Braaksma M, et al. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck. 2002; 24: 737747.
  • 11
    Franzen L, Funegard U, Ericson T, Henriksson R. Parotid gland function during and following radiotherapy of malignancies in the head and neck: a consecutive study of salivary flow and patient discomfort. Eur J Cancer. 1992; 28: 457462.
  • 12
    Bergonie J. Sur quelques formes de reactions precoses apres des irradiations [in French]. Arch Elect Med. 1911; 19: 241245.
  • 13
    Nagler R. The enigmatic mechanism of irradiation-induced damage to the major salivary glands. Oral Dis. 2002; 8: 141146.
  • 14
    Abok K, Brunk U, Jung B, et al. Morphologic and histochemical studies of the deferring radiosensitivity of the ductular and acinar cell of the rat submandibular gland. Virchows Arch Cell Pathol. 1984; 45: 443460.
  • 15
    Roesink J, Moerland M, Hoekstra A, et al. Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose-volume response relationships. Int J Radiat Oncol Biol Phys. 2004; 58: 14511460.
  • 16
    Konings A, Coppes R, Vissink A. On the mechanism of salivary gland radiosensitivity. Int J Radiat Oncol Biol Phys. 2005; 62: 11871194.
  • 17
    Valdez I. Radiation-induced salivary dysfunction: clinical course and significance. Special Care Dent. 1991; 11: 525255.
  • 18
    Eneroth C, Henrikson C, Jacobson P. Effect of fractionated radiotherapy on salivary gland function. Cancer. 1972; 30: 11471153.
  • 19
    Roesink J, Moerland M, Battermann J, et al. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2001; 51: 938946.
  • 20
    Braam P, Roesink J, Moerland M, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62: 659664.
  • 21
    Eisbruch A, Terrell J. The relationship between xerostomia and dysphagia after chemoradiation of head and neck cancer. Head Neck. 2003; 25: 1082; author reply, 1082–1083.
  • 22
    Price RE, Ang KK, Stephens LC, Peters LJ. Effects of continuous hyperfractionated accelerated and conventionally fractionated radiotherapy on the parotid and submandibular salivary glands of rhesus monkeys. Radiother Oncol. 1995; 34: 3946.
  • 23
    Van den Bogaert W, van der Schueren E, Horiot J, et al. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects. Radiother Oncol. 1995; 35: 9199.
  • 24
    Navazesh M. Methods for collecting saliva. Ann NY Acad Sci. 1993; 694: 7277.
  • 25
    Eisbruch A, Rhodus N, Rosenthal D, et al. How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol. 2003; 13: 226234.
  • 26
    Chaushu G, Bercovici M, Dori S, et al. Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer. 2000; 88: 984987.
  • 27
    Roesink J, Schipper M, Busschers W, et al. A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. Int J Radiat Oncol Biol Phys. 2005; 63: 10061009.
  • 28
    Valdes Olmos R, Keus R, Takes R, et al. Scintigraphic assessment of salivary function and excretion response in radiation-induced injury to the major salivary glands. Cancer. 1994; 73: 28862893.
  • 29
    Van Acker F, Flamen P, Lambin P, et al. The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Commun. 2001; 22: 225231.
  • 30
    Astreinidou E, Lagendijk J, Raaijmakers C, et al. 3D-MR Sialography protocol for post-radiotherapy follow up of the salivary duct system. J Magn Reson Imaging. 2006; 24: 556562.
  • 31
    Thoeny H, De Keyzer F, Boesch C, Hermans R. Diffusion-weighted imaging of the parotid gland: influence of the choice of b-values on the apparent diffusion coefficient value. J Magn Reson Imaging. 2004; 20: 786790.
  • 32
    Thoeny H, De Keyzer F, Claus F, et al. Gustatory stimulation changes the apparent diffusion coefficient of salivary glands: initial experience. Radiology. 2005; 235: 629634.
  • 33
    Cox JD, Stetz J, Pajak T. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 13411346.
  • 34
    Meirovitz A, Schipper M, Jabbari S, et al. Evaluation of xerostomia: is scoring by the physician adequate? Int J Radiat Oncol Biol Phys. 2005; 63: S130. Abstract 215.
  • 35
    [No authors listed] LENT-SOMA tables. Radiother Oncol. 1995; 35: 1760.
  • 36
    Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol. 2002; 63: 203211.
  • 37
    Trotti A, Colevas A, Setser A, et al. Common Toxicity Criteria (CTC) version 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176178.
  • 38
    Epstein J, Emerton S, Kolbinson D, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck. 1999; 21: 111.
  • 39
    Hamlet S, Faull J, Klein B, et al. Mastication and swallowing in patients with post-irradiation xerostomia. Int J Radiat Oncol Biol Phys. 1997; 37: 789796.
  • 40
    Logemann J, Pauloski B, Rademaker A, et al. Xerostomia: 12-month changes in saliva production and its relationship to perception and performance of swallow function, oral intake and diet after chemoradiation. Head Neck. 2003; 25: 432437.
  • 41
    Kendall K, McKenzie S, Leonard R, Jones C. Structural mobility in deglutition after single modality treatment of the head and neck carcinomas with radiotherapy. Head Neck. 1998; 20: 720725.
  • 42
    Rhodus N, Moller K, Colby S, Bereuter J. Dysphagia in patients with three different etiologies of salivary gland dysfunction. Ear Nose Throat J. 1995; 74: 3942.
  • 43
    Kendall K, McKenzie S, Leonard R, Jones C. Timing of swallowing events after single-modality treatment of head and neck carcinomas with radiotherapy. Ann Otol Rhinol Laryngol. 2000; 109: 767775.
  • 44
    Lazarus C. Effects of radiation therapy and voluntary manoeuvres on swallow functioning in head and neck cancer patients. Clin Commun Disord. 1993; 3: 1120.
  • 45
    Logemann J, Smith C, Pauloski B, et al. Effects of xerostomia on perception and performance of swallow function. Head Neck. 2001; 23: 317321.
  • 46
    Nelson G. Biology of taste buds and the clinical problem of taste loss. Anat Rec. 1998; 253: 7078.
  • 47
    Maes A, Huygh I, Weltens C, et al. De gustibus: time scale of loss and recovery of tastes caused by radiotherapy. Radiother Oncol. 2002; 63: 195201.
  • 48
    Rhodus N, Moller K, Colby S, Bereuter J. Articulatory speech performance in patients with salivary gland dysfunction: a pilot study. Quintessence Int. 1995; 26: 805810.
  • 49
    Roh J, Kim A, Cho M, et al. Xerostomia following radiotherapy of the head and neck affects vocal function. J Clin Oncol. 2005; 23: 30163023.
  • 50
    Meyer T, Kuhn J, Campbell B, et al. Speech intelligibility and quality of life in head and neck survivors. Laryngoscope. 2004; 114: 19771981.
  • 51
    Tatum R, Daniels R. The correlation of radiotherapy to salivary gland reduction and increased caries incidence: a caries control method. Quintessence Int. 1982; 13: 911.
  • 52
    Joyston-Bechal S, Hayes K, Davenport E, Hardie J. Caries incidence, mutans Streptococci and Lactobacilli in irradiated patients during a 12-month preventive programme using chlorhexidine and fluoride. Caries Res. 1992; 26: 384390.
  • 53
    Spak C, Johnson G, Ekstrand J. Caries incidence, salivary flow rate and efficacy of fluoride gel treatment in irradiated patients. Caries Res. 1994; 28: 388393.
  • 54
    Kumar H, Bihani V, Kumar V, et al. Osteoradionecrosis of the mandible in patients treated with definitive radiotherapy for carcinomas of oral cavity and oropharynx. A retrospective study. Indian J Dent Res. 1992; 3: 4750.
  • 55
    Specht L. Oral complications in the head and neck radiation patient. Introduction and scope of the problem. Support Care Cancer. 2002; 10: 3639.
  • 56
    Sonis S, Fey E. Oral complications of cancer therapy. Oncology. 2002; 16: 680686.
  • 57
    Beeken L, Calman F. A return to ‘normal eating’ after curative treatment for oral cancer. What are the long-term prospects? Eur J Cancer B Oral Oncol. 1994; 30: 387392.
  • 58
    Fang F, Liu Y, Tang Y, et al. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer. 2003; 100: 425432.
  • 59
    Giatromanolaki A, Sivridis E, Maltezos E, Koukourakis M. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol. 2002; 29: 1421.
  • 60
    Rojas A, Stewart F, Soranson J, et al. Fractionation studies with WR 2721: normal tissues and tumor. Radiother Oncol. 1986; 6: 5160.
  • 61
    McChesney S, Gillette E, Dewhirst M, Withrow S. Influence of WR 2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1986; 12: 19571963.
  • 62
    Thompson D, Wyrick S, Holbrook D, Chaney S. Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma. Cancer Res. 1995; 55: 28372846.
  • 63
    Andreassen C, Grau C, Lindegaard J. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol. 2003; 13: 6272.
  • 64
    Brizel D, Wasserman T, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000; 18: 33393345.
  • 65
    Wasserman T, Brizel D, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control and survival after radiotherapy for head-and-neck cancer: a 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys. 2005; 63: 985990.
  • 66
    Sasse A, De Oliviera Clark L, Sasse E, Camara C. Amifostine reduces side effects and improves complete response rates during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys. 2006; 64: 784791.
  • 67
    Brizel D, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol. 2003; 4: 378381.
  • 68
    Buentzel J, Micke O, Adamietz I, et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys. 2006; 64: 684691.
  • 69
    Anne P, Curran W. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol. 2002; 12: 1819.
  • 70
    Eisbruch A, Ship J, Martel M, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys. 1996; 36: 469480.
  • 71
    Chao KSC, Majhail N, Huang C, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control rates in patients with ororpharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001; 61: 275280.
  • 72
    Saarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck cancer: evidence of preserved salivary gland function. Radiother Oncol. 2005; 74: 251258.
  • 73
    Pacholke H, Amdur R, Morris C, et al. Late xerostomia after intensity-modulated radiation therapy versus conventional radiotherapy. Am J Clin Oncol. 2005; 28: 351358.
  • 74
    Dawson L, Anzai Y, Marsh L, et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2000; 46: 11171126.
  • 75
    Bussels B, Maes A, Hermans R, Nuyts S, Weltens C, Van den Bogaert W. Recurrences after conformal parotid-sparing radiotherapy for head and neck cancer. Radiother Oncol. 2004; 72: 119127.
  • 76
    Eisbruch A, Marsh L, Dawson L. Recurrences near base of skull after IMRT for head and neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys. 2004; 59: 2842.
  • 77
    Feng M, Jabbari S, Lin A, et al. Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. Radiother Oncol. 2005; 77: 3238.
  • 78
    Lin A, Kim H, Terrell J, et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2003; 57: 6170.
  • 79
    Jabbari S, Kim H, Feng M, et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys. 2005; 63: 725731.
  • 80
    Chao KSC, Deasy J, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001; 49: 907916.
  • 81
    Eisbruch A, Ten Haken R, Kim H, et al. Dose, volume and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999; 45: 577587.
  • 82
    Blanco AI, Chao KSC, El Naqa I, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62: 10551069.
  • 83
    Munter M, Karger C, Hoffner S, et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys. 2004; 58: 175184.
  • 84
    Chambers S, Garden AS, Rosenthal D, et al. Intensity-modulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep. 2005; 7: 131136.
  • 85
    Konings A, Cotteleer F, Faber H, et al. Volume effects and region-dependent radiosensitivity of the parotid gland. Int J Radiat Oncol Biol Phys. 2005; 62: 10901095.
  • 86
    Konings A, Faber H, Vissink A, Coppes R. Radioprotective effect of amifostine on parotid gland functioning is region dependent. Int J Radiat Oncol Biol Phys. 2005; 63: 15841591.
  • 87
    Bussels B, Maes A, Flamen P, et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol. 2004; 73: 297306.
  • 88
    Saarilahti K, Kouri M, Collan J, et al. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head neck cancer. Radiother Oncol. 2006; 78: 270275.
  • 89
    Eisbruch A, Kim H, Terrell J, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50: 695704.
  • 90
    Jellema A, Doornaert P, Slotman B, et al. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? Radiother Oncol. 2005; 77: 164171.
  • 91
    Jha N, Seikaly H, McGaw T, Coulter L. Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys. 2000; 46: 711.
  • 92
    Seikaly H, Jha N, McGaw T, et al. Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope. 2001; 111: 347352.
  • 93
    Jha N, Seikaly H, Harris J, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol. 2003; 66: 283289.
  • 94
    Seikaly H, Jha N, Harris J, et al. Long-term outcome of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg. 2004; 130: 956961.
  • 95
    Pathak K, Bhalavat R, Mistry R, et al. Upfront submandibular salivary gland transfer in pharyngeal cancers. Oral Oncol. 2004; 40: 960963.
  • 96
    Liu X, Zeng Z, Hong M, et al. Primary effect of submandibular salivary gland transfer in preventing radiation-induced xerostomia of nasopharyngeal carcinoma. Ai Zheng. 2005; 24: 577581.
  • 97
    Jellema A, Langendijk H, Bergenhenegouwen L, et al. The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer. Radiother Oncol. 2001; 59: 157160.
  • 98
    Momm F, Volegova-Neher N, Schulte-Monting J, Guttenberger R. Different saliva substitutes for treatment of xerostomia following radiotherapy: a prospective crossover study. Strahlenther Onkol. 2005; 181: 231236.
  • 99
    Epstein JB, Loh R, Stevenson-Moore P, et al. Chlorhexidine rinse in prevention of dental caries in patients following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1989; 68: 401405.
  • 100
    Epstein JB, McBride B, Stevenson-Moore P, et al. The efficacy of chlorhexidine gel in reduction of Streptococcus mutans and Lactobacillus species in patients treated with radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1991; 71: 172178.
  • 101
    Bjornstrom M, Axell T, Birkhed D. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. A multi-centre study. Swed Dent J. 1990; 14: 153161.
  • 102
    Johnson J, Ferretti G, Nethery W, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med. 1993; 329: 390395.
  • 103
    Le Veque F, Montgomery M, Potter D, et al. A multi-centre, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol. 1993; 11: 11241131.
  • 104
    Rieke J, Hafermann M, Johnson J, et al. Oral pilocarpine for radiation-induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials. Int J Radiat Oncol Biol Phys. 1995; 31: 661669.
  • 105
    Jacobs C, van der Pas M. A multi-centre maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology. 1996; 10: 1620.
  • 106
    Hamlar D, Schuller D, Gahbauer R, et al. Determination of the efficacy of topical oral pilocarpine for post-irradiation xerostomia in patients with head and neck carcinoma. Laryngoscope. 1996; 106: 972976.
  • 107
    Gornitsky M, Shenouda G, Sultanem K, et al. Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 98: 4552.
  • 108
    Ringash J, Warde P, Lockwood G, et al. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys. 2005; 61: 14031407.
  • 109
    Fox R. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjogren's syndrome. Adv Exp Med Biol. 2002; 506: 11071116.
  • 110
    Epstein JB, Burchell J, Emerton S, et al. A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1994; 77: 610614.
  • 111
    Gorsky M, Epstein JB, Parry J, et al. The efficacy of pilocarpine and bethanchol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97: 190195.
  • 112
    Delporte C, O'Connell B, Xinjun H, et al. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci USA. 1997; 94: 32683273.
  • 113
    Lombaert I, Wierenga P, Kok T, et al. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. Clin Cancer Res. 2006; 12: 18041812.